OakChart

Alpha Teknova Inc

TKNOHealthcare·Drug Manufacturers - Specialty & Generic·USA·Small·NASD·Nov 11 • 3:59 PM ET

8.62-0.11 (-1.26%)
2026-11-12 03:56 CET
Market cap
542.22 USD m
Revenue, TTM
45.95 USD m
Net income, TTM
-15.97 USD m
Free cash flow, TTM
-6.38 USD m
EPS diluted, TTM
-0.30
P/E
-
Compare

Price

TKNO against its 20, 50 and 200-day averages
2050200beat
4.006.008.002.9M5.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TKNOclose 8.6220-day 7.3850-day 7.82200-day 5.078.6252w high

9.1% under the 52-week high of 9.48 on 25 Sep 2026. 52-week low 1.91 on 11 Feb 2026. Last 15 sessions, 66.8% high to low

Volume 0.87× normal · the line is the 50-bar volume average

Profile

TKNO
52-week range, 89% of the way up
1.919.48

Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. It provides reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company was founded by Thomas E. Davis in 1996 and is headquartered in Hollister, CA.

IndexRUT
Employees158
IPOJun 25, 2021
Beta0.94
ATR, 14d0.70
Rel volume0.87
Short float12.03%
Insider own79.65%
Inst own13.45%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap542.22M
Enterprise Value552.65M
Income-15.97M
Sales45.95M
Book/sh1.11
Cash/sh0.26
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees158
IPOJun 25, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S11.80
P/B7.74
P/C32.74
P/FCF-
EV/EBITDA-
EV/Sales12.03
Quick Ratio2.72
Current Ratio3.56
Debt/Eq0.45
LT Debt/Eq0.42
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.30
EPS next Y-0.22
EPS next Q-0.08
EPS this Y12.22%
EPS next Y23.00%
EPS next 5Y17.70%
EPS past 3/5Y42.42% -
Sales past 3/5Y-0.73% 5.30%
EPS Y/Y TTM12.64%
Sales Y/Y TTM15.45%
EPS Q/Q18.85%
Sales Q/Q21.52%
EarningsNov 04 AMC
EPS/Sales Surpr.19.03% 8.48%

Ownership

Insider Own79.65%
Insider Trans0.00%
Inst Own13.45%
Inst Trans3.43%
ROA-15.79%
ROE-24.12%
ROIC-18.84%
Gross Margin33.93%
Oper. Margin-31.60%
Profit Margin-34.76%
SMA2016.79%
SMA5010.27%
SMA20070.09%
Trades-

Technical

Shs Outstand53.70M
Shs Float12.80M
Short Float12.03%
Short Ratio3.42
Short Interest1.54M
52W High9.48 -9.07%
52W Low1.91 351.31%
Volatility10.07% 9.92%
ATR (14)0.70
RSI (14)59.54
Beta0.94
Rel Volume0.87
Avg Volume450.17K
Volume390,613

Performance

Perf Week16.96%
Perf Month4.87%
Perf Quarter16.80%
Perf Half Y120.46%
Perf YTD126.84%
Perf Year75.92%
Perf 3Y342.05%
Perf 5Y-65.34%
Perf 10Y-
Recom1.25
Target Price9.83
Prev Close8.73
Price8.62
Change %-1.26%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Sep 17, 2026InitiatedJJefferiesBuy$9+4.4%
Aug 11, 2026UpgradeBBTIG ResearchNeutral → Buy$8-7.2%
Aug 05, 2026InitiatedRRoth CapitalBuy$7-18.8%
Jul 22, 2025ResumedSStephensOverweight$8-7.2%
Feb 10, 2025InitiatedCCraig HallumBuy$12+39.2%
Mar 12, 2024DowngradeBBTIG ResearchBuy → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
MRVIMaravai LifeSciences Holdings Inc2.00B
TECHBio-Techne Corp11.44B
AVTRAvantor Inc10.66B
RGENRepligen Corp11.03B
AZTAAzenta Inc2.14B
TMOThermo Fisher Scientific Inc265.92B
CTKBCytek BioSciences Inc753.32M
LABStandard BioTools Inc253.85M
HBIOHarvard Bioscience Inc44.06M
CYRXCryoPort Inc1.04B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lowell MatthewChief Financial OfficerMar 06 '26Buy2.1940,00087,616168,376Mar 09 04:30 PM
Gunstream StephenPresident and CEOMar 06 '26Buy2.1526,00055,801269,497Mar 09 04:24 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
IWCiShares Micro-Cap ETFAUM: 1.22B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.060-0.074-0.06012.7011.717
2026Q22026-08-05-0.060-0.084-0.05912.1910.957
2026Q12026-05-06-0.080-0.093-0.08511.0810.235
2025Q42026-02-26-0.090-0.093-0.0899.989.695
2025Q32025-11-06-0.080-0.094-0.08010.4510.235
2025Q22025-08-07-0.070-0.100-0.06710.299.905
2025Q12025-05-08-0.090-0.108-0.0879.809.414
2024Q42025-03-04-0.110-0.120-0.1079.278.775
2024Q32024-11-07-0.150-0.113-0.1469.589.194
2024Q22024-08-13-0.130-0.163-0.1319.619.464
2024Q12024-05-13-0.200-0.243-0.1989.298.454
2023Q42024-03-11-0.260-0.240-0.2627.878.334
2023Q32023-11-09-0.340-0.288-0.3398.178.244
2023Q22023-08-10-0.250-0.278-0.25311.539.714
2023Q12023-05-10-0.310-0.305-0.3139.128.112
2022Q42023-03-15-0.470-0.345-0.4727.897.702

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-0.610-0.655-0.35036.8935.19
2022FY-1.690-1.270-1.69041.4241.23
2023FY-1.160-1.118-1.15636.6837.14
2024FY-0.570-0.584-0.57237.7537.21
2025FY-0.320-0.330-0.32340.5240.13
2026FY--0.281--46.92
2027FY--0.216--53.81
2028FY--0.178--62.56
2029FY--0.040--85.60

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0573111.0810.6211.50
2026Q4S2026-11-0470011.0310.6211.30
2026Q4S2026-10-2170011.0310.6211.30
2026Q4S2026-10-2071011.0310.6211.30
2026Q4S2026-09-1574011.0310.6211.30
2026Q4S2026-08-1064010.9910.6211.20
2026Q4S2026-08-0764010.9910.6211.20
2026Q4S2026-08-0663010.8910.5311.20
2026Q4S2026-08-0460010.7410.4011.10
2026Q4S2026-07-2750010.7210.4011.10
2026Q4S2026-07-2150110.7210.4011.10
2026Q4S2026-05-1351210.7210.4011.10
2026Q4S2026-05-0752210.8110.4011.10
2026Q4S2026-03-0552210.8110.4610.95

Estimate history

EPS, annual-0.0550.023-0.35-1.69-1.156-0.572-0.323-0.2979
Period2019202020212022202320242025TTM
EPS, quarterly-0.146-0.107-0.087-0.067-0.08-0.089-0.085-0.059-0.065
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual20.7831.29736.89341.4236.68437.74540.5245.95
Period2019202020212022202320242025TTM
Sales, quarterly9.5769.2659.79510.28710.4549.98411.07712.18512.704
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual26.11226.11228.01228.17940.79453.4153.56253.703
Period2019202020212022202320242025MRQ
Shares, quarterly53.30353.4153.43753.51453.52453.56253.6153.68353.703
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue45.9540.5237.7436.6841.4236.8931.3020.78
Cost of Goods Sold Incl. D&A30.3628.2331.6627.5425.0920.4214.6913.08
Gross Profit15.5912.296.089.1516.3316.4716.617.70
Selling, General and Administrative Excl. Other30.1128.7730.9339.6545.1928.4811.9412.29
Research and Development2.272.202.765.577.744.311.510.79
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-14.52-16.48-24.85-30.50-28.86-12.014.66-4.59
Interest Expense0.940.710.690.83-0.59--
Unusual Expense0.480.501.305.8920.800.000.000.00
Net Income Before Taxes-15.92-17.20-26.83-37.08-49.39-12.644.73-4.54
Income Taxes0.050.06-0.09-0.30-1.92-2.831.16-3.10
Consolidated Net Income-15.97-17.26-26.75-36.78-47.47-9.803.57-1.44
Net Income From Continuing Operations-15.97-17.26-26.75-36.78-47.47-9.803.57-1.44
Net Income-15.97-17.26-26.75-36.78-47.47-9.800.61-1.44
EPS (Recurring)-0.29-0.32-0.55-1.03-1.17-0.350.02-0.06
EPS (Basic, Before Extraordinaries)-0.30-0.32-0.57-1.16-1.69-0.350.02-0.06
EPS (Diluted)-0.30-0.32-0.57-1.16-1.69-0.350.02-0.06
EBITDA-8.18-9.63-18.27-24.84-25.36-9.126.71-2.99
Non-Operating Income (Expense)0.020.480.000.140.27-0.040.060.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.142.712.903.272.931.130.220.05
Price To Sales Ratio10.405.0210.343.243.8215.55--
Gross Margin33.9330.3416.1224.9439.4244.6553.0637.05
Operating Margin-31.60-40.66-65.83-83.14-69.67-32.5514.90-22.10
Net Margin-34.76-42.59-70.86-100.26-114.60-26.571.94-6.93
Shares Outstanding53.7053.5653.4140.7928.1828.0126.1126.11
Market Capitalization542.22542.22445.12151.91158.66573.68579.85-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue12.7012.1911.089.9810.4510.299.799.27
Cost of Goods Sold Incl. D&A8.167.597.587.037.546.597.087.42
Gross Profit4.544.603.502.962.923.702.721.84
Selling, General and Administrative Excl. Other7.757.497.797.086.947.087.687.47
Research and Development0.580.550.610.520.540.580.550.59
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.21-2.89-4.30-4.13-4.02-3.39-4.96-5.63
Interest Expense0.260.250.220.210.190.170.140.13
Unusual Expense0.000.000.000.48---0.00
Net Income Before Taxes-3.46-3.14-4.51-4.82-4.21-3.55-4.62-5.76
Income Taxes0.030.030.05-0.060.080.020.02-0.04
Consolidated Net Income-3.49-3.17-4.55-4.76-4.29-3.57-4.64-5.72
Net Income From Continuing Operations-3.49-3.17-4.55-4.76-4.29-3.57-4.64-5.72
Net Income-3.49-3.17-4.55-4.76-4.29-3.57-4.64-5.72
EPS (Recurring)-0.06-0.06-0.08-0.08-0.08-0.07-0.09-0.11
EPS (Basic, Before Extraordinaries)-0.07-0.06-0.09-0.09-0.08-0.07-0.09-0.11
EPS (Diluted)-0.07-0.06-0.09-0.09-0.08-0.07-0.09-0.11
EBITDA-1.62-1.30-2.72-2.55-2.43-1.80-3.38-3.98
Non-Operating Income (Expense)0.010.000.010.000.000.000.480.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.480.490.550.610.670.750.670.61
Price To Sales Ratio10.406.973.715.028.326.747.2511.81
Gross Margin35.7337.7331.5729.6227.9235.9427.7719.87
Operating Margin-25.24-23.72-38.80-41.34-38.43-32.92-50.68-60.74
Net Margin-27.47-26.02-41.12-47.66-41.00-34.70-47.42-61.73
Shares Outstanding53.7053.6853.6153.5653.5253.5153.4453.41
Market Capitalization542.22304.53154.87203.41331.26262.39277.34445.12

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments21.3430.4028.4842.2487.525.139.68
Short Term Receivables4.624.313.954.285.856.572.99
Inventories7.056.8011.5912.255.393.582.57
Other Current Assets1.501.271.632.372.441.140.19
Total Current Assets34.5142.7845.6661.14101.2016.4115.42
Net Property, Plant & Equipment55.8461.5266.8471.3129.8110.015.45
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets11.9413.0914.2417.5635.3236.4737.61
Deferred Tax Assets8.40------
Other Assets1.281.381.852.250.180.020.03
Total Assets111.98118.77128.59152.26166.5162.9158.51
Short Term Debt Incl. Current Port. of LT Debt1.885.841.802.220.000.000.04
Accounts Payable1.380.821.492.452.251.640.77
Other Current Liabilities4.284.545.586.205.502.334.77
Total Current Liabilities7.5411.218.8810.887.743.965.58
Long Term Debt26.3924.3328.6640.0911.870.000.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities9.280.830.921.223.155.993.90
Other Liabilities0.000.010.100.190.540.550.48
Total Liabilities43.2136.3838.5552.3823.3110.519.96
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0035.6435.64
Common Equity68.7882.3990.0499.89143.2016.7712.91
Total Shareholders Equity68.7882.3990.0499.89143.2052.4148.55
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity68.7882.3990.0499.89143.2052.4148.55
Total Liabilities & Stockholders Equity111.98118.77128.59152.26166.5162.9158.51
Book Value Per Share1.281.542.213.545.110.640.49
Tangible Book Value Per Share1.061.301.862.923.85-0.75-0.95
Full-Time Employees158173211290237194-
Price to Book Ratio7.745.101.521.424.013.97-
Return on Assets-14.96-21.62-26.19-29.78-8.555.88-
Return on Equity-22.83-31.02-38.73-39.05-10.027.07-
Return on Invested Capital-18.14-25.06-30.99-33.91-6.326.81-2.97
Quick Ratio3.643.213.844.5012.373.242.30
Current Ratio4.583.825.145.6213.074.142.76

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-15.97-17.26-26.75-36.78-47.47-9.803.57-1.44
Depreciation6.346.346.585.663.492.882.041.64
Other Funds (Non Cash)4.424.808.7210.3125.842.390.310.09
Funds from Operations-5.17-6.07-11.54-21.11-20.07-7.378.01-2.68
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.40-2.68-0.872.25-7.33-1.70-5.515.09
Cash from Operating Activities-5.57-8.75-12.42-18.86-27.40-9.072.502.41
Capital Expenditures-0.81-1.15-1.12-7.93-28.15-19.88-5.47-2.85
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.120.200.000.000.000.00
Purchase or Sale of Investments9.2611.85-26.270.000.001.833.70-5.57
Purchase of Investments-15.24-17.15-30.270.000.000.00-1.76-6.65
Sale Or Maturity of Investments24.5029.004.000.000.001.835.471.08
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.530.030.06
Cash from Investing Activities8.4510.70-27.27-7.74-28.15-17.52-1.74-8.36
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock0.400.2115.2722.830.4499.060.00-26.22
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00-26.49
Sale of Common Pref Stock0.400.2115.2722.830.4499.060.000.27
Proceedsfrom Stock Options0.110.1115.2422.750.2999.060.000.00
Issuance or Reduction of Debt, Net0.000.000.00-10.009.9611.74-0.0434.77
Change in Long Term Debt0.000.000.00-10.009.9611.74-0.0434.77
Issuance of Long Term Debt0.001.110.000.009.9611.740.0035.64
Reduction of Long Term Debt0.00-1.110.00-10.000.000.00-0.04-0.86
Net Financing Active Other Cash Flow0.150.04-0.350.01-0.140.00-1.550.00
Other Financing Activities Uses-0.28-0.29-0.74-0.99-0.140.00-1.550.00
Cash from Financing Activities0.550.2514.9112.8510.27110.79-1.608.55
Net Change in Cash3.432.20-24.78-13.75-45.2884.20-0.832.60
Free Cash Flow-6.38-9.89-13.54-26.80-55.55-28.95-2.96-0.44
Preferred Dividends (Cash Flow)-0.000.000.000.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.05-0.09-0.30-1.93-2.842.09-2.97

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments16.5617.4417.7821.3422.1224.00
Short Term Receivables5.825.415.674.625.135.14
Inventories7.486.916.877.056.917.61
Other Current Assets1.941.071.341.502.401.31
Total Current Assets31.8030.8231.6734.5136.5638.06
Net Property, Plant & Equipment50.7352.5654.1355.8457.5258.56
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets11.0811.3711.6611.9412.2312.52
Deferred Tax Assets---8.40--
Other Assets1.081.131.201.281.311.35
Total Assets94.6895.8898.66111.98107.62110.49
Short Term Debt Incl. Current Port. of LT Debt2.001.961.921.881.891.89
Accounts Payable1.811.441.621.381.081.20
Other Current Liabilities5.113.483.364.283.973.39
Total Current Liabilities8.936.876.907.546.946.48
Long Term Debt24.9825.4525.9126.3927.0927.08
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.990.960.939.280.950.87
Other Liabilities0.000.000.000.000.000.00
Total Liabilities34.9033.2833.7343.2134.9834.43
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity59.7862.6064.9268.7872.6576.06
Total Shareholders Equity59.7862.6064.9268.7872.6576.06
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity59.7862.6064.9268.7872.6576.06
Total Liabilities & Stockholders Equity94.6895.8898.66111.98107.62110.49
Book Value Per Share1.111.171.211.281.361.42
Tangible Book Value Per Share0.910.950.991.061.131.19
Full-Time Employees---158--
Price to Book Ratio7.744.692.252.804.363.34
Return on Assets-15.79-16.25-16.15-14.96-15.73-19.04
Return on Equity-24.12-24.19-23.92-22.83-22.79-27.74
Return on Invested Capital-4.12-3.60-5.01-5.00-4.30-3.46
Quick Ratio2.723.483.603.644.274.70
Current Ratio3.564.494.594.585.275.87

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-3.49-3.17-4.55-4.76-4.29-3.57
Depreciation1.591.591.581.581.591.59
Other Funds (Non Cash)1.031.091.061.241.461.37
Funds from Operations-0.84-0.45-1.87-2.01-1.15-0.59
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.44-0.02-1.491.55-0.83-1.61
Cash from Operating Activities-1.28-0.47-3.36-0.46-1.98-2.20
Capital Expenditures-0.12-0.12-0.22-0.35-0.39-0.21
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments1.582.072.063.562.032.23
Purchase of Investments-3.92-3.93-3.94-3.44-3.97-7.76
Sale Or Maturity of Investments5.506.006.007.006.0010.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities1.461.951.843.211.642.03
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.060.220.010.110.030.07
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.060.220.010.110.030.07
Proceedsfrom Stock Options0.000.050.000.060.000.06
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.390.00-0.10-0.140.240.00
Other Financing Activities Uses-0.040.00-0.10-0.14-0.090.00
Cash from Financing Activities0.450.22-0.09-0.040.270.07
Net Change in Cash0.631.70-1.612.71-0.07-0.10
Free Cash Flow-1.40-0.60-3.58-0.81-2.37-2.41

Revenue breakdown

Clinical Solutions2024: 7.10M 2025: 7.65M
Lab Essentials2024: 28.88M 2025: 31.04M
Other Product2024: 1.77M 2025: 1.83M
Non-US2024: 1.83M 2025: 2.27M
United States2024: 35.92M 2025: 38.25M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.03%1.5M12.8M414.11K
2026-10-1515.09%1.6M10.9M237.38K
2026-09-3014.96%1.6M10.9M217.56K
2026-09-1514.45%1.6M10.9M211.69K
2026-08-3114.28%1.6M10.9M216.86K
2026-08-1414.63%1.6M10.9M203.08K
2026-07-3113.73%1.5M10.9M167.26K
2026-07-1514.52%1.6M10.9M167.57K
2026-06-3011.54%1.3M10.9M163.13K
2026-06-159.03%1.0M10.9M131.55K
2026-05-2910.23%1.1M10.9M126.53K
2026-05-1511.70%1.3M10.9M129.31K
2026-04-3012.11%1.3M10.8M187.49K
2026-04-1512.42%1.3M10.7M223.40K
2026-03-3112.52%1.3M10.8M231.46K
2026-03-1312.33%1.3M10.8M249.88K
2026-02-2713.06%1.4M10.8M237.72K
2026-02-1312.55%1.4M10.8M238.11K
2026-01-3013.40%1.4M10.8M200.53K
2026-01-1515.14%1.6M10.8M176.99K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.505.407.000.0010.9320.000.000.973-0.0250.001
call5.003.304.502.855.5918.000.000.942-0.0230.002
call7.500.902.100.982.9664.000.000.767-0.0350.004
call10.000.001.050.142.87722.000.000.458-0.0870.005
call12.500.000.950.003.7670.000.000.367-0.1080.005
put2.500.000.950.004.5600.000.00-0.017-0.0150.001
put5.000.000.100.032.5548030.00-0.058-0.0220.002
put7.500.050.250.901.46446.000.00-0.233-0.0340.004
put10.000.551.852.651.7790.000.00-0.542-0.0860.005
put12.502.904.200.002.4220.000.00-0.633-0.1070.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-218-KCurrent report2026-10-20SEC
2026-10-21424B5SEC
2026-10-20424B5SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-14SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-018-KCurrent report2026-05-27SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-05-04SEC
2026-04-21ARSAnnual report to security holders. 2025-12-31SEC
2026-04-21DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-21DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-21SEC
2026-03-094Statement of changes in beneficial ownership of securities2026-02-15SEC
2026-03-094Statement of changes in beneficial ownership of securities2026-02-15SEC
2026-03-094Statement of changes in beneficial ownership of securities2026-02-15SEC
2026-03-0210-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-268-KCurrent report2026-02-26SEC
2025-11-0710-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC
2025-11-068-KCurrent report2025-11-06SEC
2025-08-0810-QQuarterly report pursuant to Section 13 or 15(d)2025-06-30SEC
2025-08-078-KCurrent report2025-08-07SEC
2025-07-16EFFECTEffectiveness filing by commission orderSEC
2025-07-14CORRESPSEC
2025-07-14UPLOADUpload SubmissionSEC
2025-07-10S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-03143.42K200
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC3.01%
ROYCE & ASSOCIATES LP2.94%
BlackRock, Inc.1.64%
Roubaix Capital, LLC1.26%
UBS Group AG0.83%
GEODE CAPITAL MANAGEMENT, LLC0.59%
Conestoga Capital Advisors, LLC0.59%
BANK OF AMERICA CORP /DE/0.48%
Squarepoint Ops LLC0.41%
Nuveen, LLC0.33%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.76%
ROYCE MICRO-CAP TRUST, INC.1.95%
Royce Micro-Cap Fund0.87%
iShares Russell 2000 ETF0.57%
Royce Capital Fund - Micro-Cap Portfolio0.28%
Fidelity Small Cap Index Fund0.23%
VANGUARD EXTENDED MARKET INDEX FUND0.21%
iShares Russell 2000 Growth ETF0.18%
iShares Russell 2000 Value ETF0.15%
iShares Biotechnology ETF0.14%

OakChart. TKNO. Cached 15 minutes.